esophageal cancer
Conditions
Interventions
S-1 treatment (day1-28)
Sponsors
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) advanced or recurrent esophageal cancer proven histologically 2) aged >= 20 years old 3) ECOG PS of 0, 1 or 2 4) resistant or intolerable existing treatments 5) adequate food intake 6) with measurable lesions 7) Adequate organ functions 8) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Previous treatment with S-1 2) With active diseases (interstitial pneumonia, fibroid lung, intestinal obstruction, uncontrollable diabetes millutus or hypertentsion, history of myocardial infarction within 6 months, or unstable angina pectoris, liver cirrhosis, renal failure) 3) Simultaneous or metachronous cancers, with the exception of tumor curable with therapy before diagnosis of esophageal cancer 4) History of severe allergic reactions to pyrimidine fluoride drug 5) Active infection 6) With severe diarrhea 7) With symptomatic metastasis to nerve 8) Psychosis 9) Patients requiring the administration of flucytosine, phenytoin or warfarin potassium 10) Pregnant or lactating women, women of childbearing potential or women who like to have children in future 11) Participant to other clinical trials 12) Any patients judged by the investigator to be unfit to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival | — |
Countries
Japan
Contacts
Public ContactYoshito Hayashi
Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology
Outcome results
None listed